Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

被引:4
|
作者
Cottrell, Christopher A. [1 ]
Manne, Kartik [2 ,3 ,4 ]
Kong, Rui [5 ]
Wang, Shuishu [5 ]
Zhou, Tongqing [5 ]
Chuang, Gwo-Yu [5 ]
Edwards, Robert J. [2 ,3 ,4 ]
Henderson, Rory [2 ,3 ,4 ]
Janowska, Katarzyna [2 ,3 ,4 ]
Kopp, Megan [2 ,3 ,4 ]
Lin, Bob C. [5 ]
Louder, Mark K. [5 ]
Olia, Adam S. [5 ]
Rawi, Reda [5 ]
Shen, Chen-Hsiang [5 ]
Taft, Justin D. [5 ]
Torres, Jonathan L. [1 ]
Wu, Nelson R. [1 ]
Zhang, Baoshan [5 ]
Doria-Rose, Nicole A. [5 ]
Cohen, Myron S. [6 ,7 ,8 ]
Haynes, Barton F. [2 ,3 ]
Shapiro, Lawrence [5 ]
Ward, Andrew B. [1 ]
Acharya, Priyamvada [2 ,3 ,4 ,5 ]
Mascola, John R. [5 ]
Kwong, Peter D. [5 ,9 ]
机构
[1] Scripps Res Inst, Dept Integrat Struct & Computat Biol, Consortium HIV AIDS Vaccine Dev CHAVD, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[2] Duke Univ, Sch Med, Human Vaccine Inst, Dept Med, Durham, NC 27710 USA
[3] Duke Univ, Sch Med, Human Vaccine Inst, Dept Surg, Durham, NC 27710 USA
[4] Duke Univ, Ctr HIV AIDS Vaccine Immunol Immunogen Discovery, Durham, NC 27710 USA
[5] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[6] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
[7] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA
[8] Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA
[9] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA
来源
CELL REPORTS | 2021年 / 37卷 / 05期
基金
美国国家科学基金会;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED GLYCAN; HIV-1-NEUTRALIZING ANTIBODIES; MATURATION PATHWAY; GERMLINE; REVEALS; MODEL; SITE; BINDING; IDENTIFICATION;
D O I
10.1016/j.celrep.2021.109922
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recognition of N-linked glycan at residue N276 (glycan276) at the periphery of the CD4-binding site (CD4bs) on the HIV-envelope trimer is a formidable challenge for many CD4bs-directed antibodies. To understand how this glycan can be recognized, here we isolate two lineages of glycan276-dependent CD4bs antibodies. Antibody CH540-VRC40.01 (named for donor-lineage.clone) neutralizes 81% of a panel of 208 diverse strains, while antibody CH314-VRC33.01 neutralizes 45%. Cryo-electron microscopy (cryo-EM) structures of these two antibodies and 179NC75, a previously identified glycan276-dependent CD4bs antibody, in complex with HIV-envelope trimer reveal substantially different modes of glycan276 recognition. Despite these differences, binding of glycan276-dependent antibodies maintains a glycan276 conformation similar to that observed in the absence of glycan276-binding antibodies. By contrast, glycan276-independent CD4bs antibodies, such as VRC01, displace glycan276 upon binding. These results provide a foundation for understanding antibody recognition of glycan276 and suggest its presence may be crucial for priming immunogens seeking to initiate broad CD4bs recognition.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
    Haynes, Barton F.
    Wiehe, Kevin
    Borrrow, Persephone
    Saunders, Kevin O.
    Korber, Bette
    Wagh, Kshitij
    McMichael, Andrew J.
    Kelsoe, Garnett
    Hahn, Beatrice H.
    Alt, Frederick
    Shaw, George M.
    NATURE REVIEWS IMMUNOLOGY, 2023, 23 (03) : 142 - 158
  • [32] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Cohen, Yehuda Z.
    Caskey, Marina
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 366 - 373
  • [33] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
    Barton F. Haynes
    Kevin Wiehe
    Persephone Borrow
    Kevin O. Saunders
    Bette Korber
    Kshitij Wagh
    Andrew J. McMichael
    Garnett Kelsoe
    Beatrice H. Hahn
    Frederick Alt
    George M. Shaw
    Nature Reviews Immunology, 2023, 23 : 142 - 158
  • [34] Broadly neutralizing antibodies: An approach to control HIV-1 infection
    Yaseen, Mahmoud Mohammad
    Yaseen, Mohammad Mahmoud
    Alqudah, Mohammad Ali
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2017, 36 (01) : 31 - 40
  • [35] Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
    Zhang, Zhiqing
    Li, Shaowei
    Gu, Ying
    Xia, Ningshao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
  • [36] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Awan, Seemal F.
    Happe, Myra
    Hofstetter, Amelia R.
    Gama, Lucio
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (04) : 247 - 257
  • [37] HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies
    Misra, Milind
    Jeffy, Jeffy
    Liao, Charis
    Pickthorn, Stephanie
    Wagh, Kshitij
    Herschhorn, Alon
    BIOINFORMATICS, 2024, 40 (03)
  • [38] Role of Broadly Neutralizing Antibodies in the Controlling of HIV-1 Infection
    Yildirmak, Taner
    KLIMIK JOURNAL, 2019, 32 (02) : 112 - 116
  • [39] Broadly neutralizing antibodies against HIV-1: Templates for a vaccine
    van Gils, Marit J.
    Sanders, Rogier W.
    VIROLOGY, 2013, 435 (01) : 46 - 56
  • [40] Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
    Liu, Yubin
    Cao, Wei
    Sun, Ming
    Li, Taisheng
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 194 - 206